In the Company’s submission that reanalyzed the data from previous studies of Androxal, it also reviewed with the FDA the variability of morning testosterone levels from day to day. Over a six-month period, men on placebo moved in and out of the normal range for morning testosterone. In that submission the Company noted, “The sponsor believes this finding raises one other consideration. Given that a variety of factors can cause episodes of low testosterone, we believe starting all men on exogenous testosterone is not appropriate. Once exogenous testosterone therapy is initiated a subject would be relegated to such therapy due to the suppressive effects on pituitary responsiveness. A drug such as Androxal would allow men who exhibit episodes of low T to be treated in a fashion that does not impair pituitary responsiveness. This is particularly true for younger men. As the male ages and the testes no longer are capable of responding to pituitary stimulatory signals, exogenous preparations of testosterone would be appropriate treatments.”About Repros Therapeutics Inc.
Repros Therapeutics® Receives IRB Approval To Commence Phase IIb Study Of Androxal® In The Treatment Of Secondary Hypogonadism
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.